PGx News

  • Sun, December 13, 2020 2:43 PM | Anonymous

    Deadline: January 01, 2021
    Link

  • Sun, December 13, 2020 2:41 PM | Anonymous

    Deadline: Feb 02, 2021
    PGx of Adverse Drug Reactions
    Link

  • Sun, December 13, 2020 2:38 PM | Anonymous

    Due date: April 01, 2021
    Special Issue of CPT: Pharmacogenetics & Pharmacogenomics
    Link

  • Sun, December 06, 2020 2:42 PM | Anonymous

    Charlie Paulding, PhD, representing PGRN, will be a speaker at the "Polygenic Risk Scores: Current Status and Future Utility" virtual conference being held Wed Feb 17.  Information

  • Sun, December 06, 2020 2:37 PM | Anonymous

    Kathy Giacomini, President of PGRN, will be a Key Note Speaker at the World Congress of Basic & Clinical Pharmacology - WCP 2022 being held in Glasgow, Scotland, July 17-22, 2022. For information: http://wcp2022.org

  • Sun, December 06, 2020 2:34 PM | Anonymous

    We are proud to announce that PGRN has entered into an agreement with ASCPT to publish at least 2 educational tutorials, White Papers or submissions for a Themed Issue. Kathy Giacomini will Chair the PGRN Journal Committee.

  • Mon, November 02, 2020 8:30 AM | Anonymous

    "Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies"

    https://www.futuremedicine.com/doi/10.2217/pgs-2020-0056

    "Evaluating the current level of pharmacists’ pharmacogenomics knowledge and its impact on pharmacogenomics implementation"

    https://www.futuremedicine.com/doi/10.2217/pgs-2020-0076

  • Mon, September 28, 2020 10:58 AM | Anonymous

    The reporting guideline for pharmacogenetic studies (STROPS) has recently been published in PLOS Med.
    https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003344

  • Wed, July 01, 2020 12:24 AM | Sook Wah Yee (Administrator)

    After 20 years of National Institute of Health funding, the Pharmacogenomics Research Network, PGRN, is now independent scientific society on July 1st, 2020.  Thank you for your membership support to establish the new PGRN! The transition is complete, and we have exceeded our membership goals and are off to a great start!

    The PGRN Officers and Councilors have a lot planned for the coming months. The mission of the Pharmacogenomics Research Network, henceforth referred to as the “Network” is to catalyze and lead research in precision medicine for the discovery and translation of genomic variation influencing therapeutic and adverse drug effects.  This will be accomplished by: 1) providing a forum to advance, promote, support, encourage and facilitate communication among researchers, educators and practitioners in pharmacogenomics and related sciences through scientific meetings, seminars, publications and related activities; 2) advancing and promoting research in pharmacogenomics; and 3) providing awareness of the national and international importance of pharmacogenomics.

    For PGRN members, please don’t forget to join us on July 17 at 11 AM Eastern Time for the inaugural Research In Progress (RIPS) webinar by Alan Shuldiner, MD. Dr. Shuldiner will speak on "Building bridges between industry, academia, health care systems and communities to advance Precision Medicine". A schedule of upcoming RIPS webinars can be found here. If you are interested in joining the PGRN, you can become a member at www.pgrn.org.


  • Wed, May 13, 2020 12:19 PM | Deleted user

    Overview

    We are pleased to announce a new fellowship sponsored by UCSF and Genentech, and focused on regulatory science. In the past decade, a plethora of new healthcare products have been developed, including innovative drugs and biologics, genome and cell-based therapies, mobile health products and implantable devices. Corresponding to the surge in these innovative products, there has been a scarcity of well-trained individuals to expertly develop and evaluate them for safe and effective use. Importantly, there is a new need for individuals who have computational training to apply their skills to the development of drugs, biologics, and medical diagnostics. The educational mission of UCSF in regulatory science is to train a new generation of scientists by providing opportunities to broaden their knowledge about tools, methods, and standards to support regulatory science and medical product development. The UCSF/Genentech postdoctoral fellowship is an experiential program that will provide the most outstanding postdocs with unique immersion experiences in regulatory science research and drug development in areas such as Clinical Pharmacology and Pharmacometrics.


    Training Components

    Our objective is that the fellow should have a sufficient foundation and breadth in his/her training to engage in and serve as an ambassador for regulatory science research and education. The fellow will receive a monthly stipend commensurate with education level and experience. The fellow will spend the first year at UCSF, and the second year, when projects are available, the fellow will have an opportunity to train at the FDA. This period of time is flexible, from 3 to 12 months. At the end of two years, the fellow will complete an additional year (after completion of the academic and FDA rotations) at Genentech, Inc. The anticipated start date of the first year fellowship in academia will be on or around August 1, 2020. The fellowship components are:


    Research and Training at UCSF (~1 year)

    During the first year, the fellow is expected to spend at least 90% of his/her time on a scientific research project. The research project will either extend an existing project or will be an entirely new one-year project. In addition to research, the fellow will be expected to complete UCSF-Stanford CERSI courses focusing on regulatory science and drug development and actively participate in UCSF-Stanford CERSI scientific seminars and symposia. Furthermore, the fellow will take part in regularly scheduled networking and mentoring events.


    Immersion Experience at FDA (3-12 months)

    During the second year, the fellow, under the mentorship of faculty, will seek training opportunities at the FDA through FDA funding mechanisms such as ORISE. The fellow will be paired with a mentor at the FDA and will work alongside clinicians, engineers, or other scientists in regulatory science research with a focus in Clinical Pharmacology and/or Pharmacometrics. The fellow will either continue his/her research project or will be involved in a new project. Research projects interests will be discussed with the fellow during his/her first year. The fellow will have an opportunity to attend seminars and workshops held at the FDA augmenting the fellow’s learning experience about different aspects of regulatory science and drug development. Furthermore, the fellow will be required to attend an annual UCSF-Stanford CERSI symposium in regulatory science.


    Immersion Experience in Industry (1 year)

    At the end of two years, the fellow will complete an additional year (after completion of the academic and FDA rotations) at Genentech, Inc. This year will complement and extend his/her training in regulatory science, drug development, Clinical Pharmacology, and Pharmacometrics. The fellow will be assigned a mentor at Genentech, Inc. and will work alongside scientists in the Department of Clinical Pharmacology at Genentech while continuing to be mentored by his/her academic faculty. The mentors will help the fellow design the research project. The fellow will be required to attend an annual UCSF-Stanford CERSI symposium in regulatory science.


    Statement of Completion and Employment

    Fellows will receive a document certifying their participation in the regulatory science fellowship upon completion of all training components. Immersive experiences in academia and at the FDA do not guarantee job placements.


    Eligibility Criteria

    Applicants must hold a PhD-level degree in pharmaceutical sciences, chemical and biomedical engineering, applied mathematics, or biomedical sciences or another related field, or hold a PharmD degree. Preferably the candidate has experience of mathematical modeling and simulation in pharmacology or biology (e.g. population PK/PD modeling, PBPK, quantitative systems pharmacology, biology) or experience in transporter biology. The candidate must have an excellent record of achievement. Due to the fact that the Fellow will perform work at the FDA, all candidates must be a U.S. citizen or otherwise meet the ORISE Non-U.S. Citizen Requirements (https://orise.orau.gov/fda/applicants/default.html#immigrant). If the Fellow is not approved for a rotation at FDA, intense didactic courses and other training in FDA regulatory sciences will be arranged during the first year training at UCSF. Applicants cannot be current FDA employees, contractors, or fellows.


    Application Process

    Applicants are to submit items 1-6 of the required documents in the order listed below as a single PDF via email by Monday, June 15, 2020 to Lawrence.Lin@ucsf.edu. The PDF filename should follow this format: “LastName_UCSF/Genentech Fellowship Application.pdf”.

    The following documents are required for a complete application:

    1. Application cover page stating: Applicant’s First and Last Name, Highest Degree, Degree Granting Institution, Current Affiliation, Email Address, Phone Number, Street Address, City, State/Country, Postal Code.
    2. Statement of interest (1,000 word maximum) describing the applicant’s professional background and qualifications, regulatory science interests, skills to be acquired, and career goals, including how the fellowship would support those goals
    3. Curriculum vitae (5 page maximum)
    4. Scientific publications or other writing samples (submit up to 2 publications). Applicant should indicate authorship role in the samples provided (i.e., primary drafter or other role). Publications are intended to gauge the research and writing capability of applicants and do not necessarily need to be on the topic of regulatory science.
    5. One letter of reference from the current research advisor to be submitted directly via email to Lawrence.Lin@ucsf.edu and must be received by the application deadline.
    6. Names of two additional references with complete contact information.


    Selection Process

    Applications will be reviewed by UCSF faculty and Genentech scientists.

    The UCSF/Genentech postdoctoral fellowship in regulatory science is supported in part by Genentech, Inc.




Copyright © 2020 the Pharmacogenomics Global Research Network. All Rights Reserved.

PGRN is a 501(c)3 Non-Profit Association

Follow PGRN
on Social Media

Become a Member

PGRN logo
Membership dues are vital to continue the mission and work of the PGRN. Join your colleagues today and suport the work of PGRN. 
Powered by Wild Apricot Membership Software